121 related articles for article (PubMed ID: 38557537)
21. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
22. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
Ritts RE; Nagorney DM; Jacobsen DJ; Talbot RW; Zurawski VR
Pancreas; 1994 Nov; 9(6):707-16. PubMed ID: 7846013
[TBL] [Abstract][Full Text] [Related]
23. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
24. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
26. Predicting Neonatal Hyperbilirubinemia Using First Day Serum Bilirubin Level in Late Preterm and Term Healthy Newborn.
Khan KA; Alam J; Nahar N; Dey SK; Mannan MA; Shahidullah M
Mymensingh Med J; 2017 Oct; 26(4):854-862. PubMed ID: 29208875
[TBL] [Abstract][Full Text] [Related]
27. Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer.
Pålsson B; Masson P; Andrén-Sandberg A
Eur J Surg Oncol; 1997 Apr; 23(2):151-6. PubMed ID: 9158191
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Serum CA72-4 and CEA Levels in Patient with Endoscopically Suspected Gastric Carcinoma.
Rehena Z; Ghosh CK; Afroz F; Alam MB; Ferdousi S; Mahmuduzzaman M; Sultana T; Ahmed AN
Mymensingh Med J; 2015 Jul; 24(3):542-9. PubMed ID: 26329953
[TBL] [Abstract][Full Text] [Related]
29. Preoperative Platelet-Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis.
Rammohan A; Cherukuri SD; Palaniappan R; Perumal SK; Sathyanesan J; Govindan M
World J Surg; 2015 Sep; 39(9):2323-8. PubMed ID: 25917199
[TBL] [Abstract][Full Text] [Related]
30. Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
Antonić J; Rakar S
Eur J Gynaecol Oncol; 1996; 17(1):29-35. PubMed ID: 8750512
[TBL] [Abstract][Full Text] [Related]
31. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy.
Maire F; Voitot H; Aubert A; Palazzo L; O'Toole D; Couvelard A; Levy P; Vidaud M; Sauvanet A; Ruszniewski P; Hammel P
Am J Gastroenterol; 2008 Nov; 103(11):2871-7. PubMed ID: 18775021
[TBL] [Abstract][Full Text] [Related]
32. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.
Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; van Dalen A; Einarsson R
Cancer; 2000 Jul; 89(1):83-8. PubMed ID: 10897004
[TBL] [Abstract][Full Text] [Related]
33. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
34. Role of Endoscopic Ultrasound Guided Fine Needle Aspiration in the Diagnosis of Pancreatic Lesions.
Alam AT; Chowdhury AK; Das CR; Ahmed SU; Yousuf NA
Mymensingh Med J; 2019 Apr; 28(2):347-351. PubMed ID: 31086149
[TBL] [Abstract][Full Text] [Related]
35. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
Duffy MJ; Sturgeon C; Lamerz R; Haglund C; Holubec VL; Klapdor R; Nicolini A; Topolcan O; Heinemann V
Ann Oncol; 2010 Mar; 21(3):441-447. PubMed ID: 19690057
[TBL] [Abstract][Full Text] [Related]
36. IETA Ultrasonic Features Combined with GI-RADS Classification System and Tumor Biomarkers for Surveillance of Endometrial Carcinoma: An Innovative Study.
Lin D; Wang H; Liu L; Zhao L; Chen J; Tian H; Gao L; Wu B; Zhang J; Guo X; Hao Y
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428723
[No Abstract] [Full Text] [Related]
37. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study.
Malesci A; Montorsi M; Mariani A; Santambrogio R; Bonato C; Bissi O; Tacconi M; Wizemann G; Spina G
Pancreas; 1992; 7(4):497-502. PubMed ID: 1641392
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.
Fujii Y; Albers GH; Carre-Llopis A; Escribano MJ
Br J Cancer; 1987 Oct; 56(4):495-500. PubMed ID: 3479995
[TBL] [Abstract][Full Text] [Related]
39. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions.
Cwik G; Wallner G; Skoczylas T; Krzyzanowski M; Ciechainski A; Madro P
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):213-8. PubMed ID: 16146081
[TBL] [Abstract][Full Text] [Related]
40. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
